DAX24.292 +1,4%Est505.882 +1,1%MSCI World4.343 -0,1%Top 10 Crypto9,6700 -0,1%Nas25.145 +1,0%Bitcoin66.517 +2,2%Euro1,1768 +0,3%Öl108,8 -4,6%Gold4.632 +0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Amazon 906866 Microsoft 870747 Alphabet A (ex Google) A14Y6F Rheinmetall 703000 Infineon 623100 Apple 865985 NEL ASA A0B733 SAP 716460 Siemens Energy ENER6Y Mercedes-Benz Group (ex Daimler) 710000 Deutsche Telekom 555750 BASF BASF11 Lufthansa 823212 Meta Platforms (ex Facebook) A1JWVX
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach EZB-Entscheid: DAX geht über 24.000-Punkte-Marke ins lange Wochenende -- Apple meldet starke Zahlen -- Reddit, Rivian, VW, RTL, Eli Lilly, Novo Nordisk im Fokus
Top News
Chip-Rally mit Hindernissen: Aktien von Intel & Micron im Aufwind, während AMD nach Rekordhoch pausiert Chip-Rally mit Hindernissen: Aktien von Intel & Micron im Aufwind, während AMD nach Rekordhoch pausiert
Sell in May und Jahrensendrally: Was ist dran an den Börsenweisheiten? Sell in May und Jahrensendrally: Was ist dran an den Börsenweisheiten?
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Amgen Aktie

Kaufen
Verkaufen
Amgen Aktien-Sparplan
290,25 EUR +0,45 EUR +0,16 %
BMN
328,90 USD -17,54 USD -5,06 %
BTT
finanzen.net zero
Amgen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.155,43 Mrd. EUR

KGV23,01Div. Rendite2,91%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN867900

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS0311621009

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAMGN

Amgen Aktien News

DatumMeistgelesen
PR NewswireAMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
PR NewswireAMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
PR NewswireAMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
Wer­bungAmgen-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireFDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
PR NewswireAMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND
PR NewswireAMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
PR NewswireFDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
PR NewswireAMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
PR NewswireAMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
PR NewswireAMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS
PR NewswireFDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
PR Newswire/C O R R E C T I O N -- Amgen/
PR NewswireAMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
PR NewswireLANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
PR NewswireAMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
PR NewswireAMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
PR NewswireAMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS
PR NewswireAMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE
PR NewswireREPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
PR NewswireAMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
PR NewswireAMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS
PR NewswireAMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
PR NewswireRESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
PR NewswireAMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
PR NewswireAMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY
PR NewswireAMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
PR NewswireIMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
PR NewswireAMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
PR NewswireCIBC introduces additional U.S. Canadian Depositary Receipts ("CDRs")
PR NewswireCIBC introduces additional U.S. Canadian Depositary Receipts ("CDRs")
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS
PR NewswireAMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
PR NewswireIMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

Amgen News

Amgen News: auf dieser Seite finden Sie alle Amgen News und Nachrichten zur Amgen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Amgen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Amgen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.